Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PALATIN TECHNOLOGIES, INC.

(PTN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
0.7149(c) 0.57(c) 0.5545(c) 0.5255(c) 0.5505(c) Last
51 520 121 19 283 315 10 423 784 10 470 746 17 604 317 Volume
-16.39% -20.27% -2.72% -5.23% +4.76% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 2,31 M - -
Net income 2022 -29,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,59x
Yield 2022 -
Sales 2023 7,14 M - -
Net income 2023 -27,7 M - -
Net Debt 2023 - - -
P/E ratio 2023 -4,79x
Yield 2023 -
Capitalization 127 M 127 M -
Capi. / Sales 2022 55,1x
Capi. / Sales 2023 17,8x
Nbr of Employees 26
Free-Float 95,6%
More Financials
Company
Palatin Technologies, Inc. (Palatin), is a biopharmaceutical company. Palatin is focused on developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Palatin product candidates are targeted receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system has... 
More about the company
Ratings of Palatin Technologies, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about PALATIN TECHNOLOGIES, INC.
11/30Palatin Gets US Patent to Use Melanocortin Peptides to Treat Immune System Dysregulatio..
MT
11/29Top Premarket Gainers
MT
11/24HC Wainwright Adjusts Palatin Technologies' Price Target to $5 From $2, Keeps Buy Ratin..
MT
11/15PALATIN TECHNOLOGIES : Reports First Quarter Fiscal Year 2022 Resultsand Provides Corporat..
PU
11/15PALATIN TECHNOLOGIES INC : Results of Operations and Financial Condition (form 8-K)
AQ
11/15Earnings Flash (PTN) PALATIN TECHNOLOGIES Reports Q1 Revenue $159,482, vs. Street Est o..
MT
11/15PALATIN TECHNOLOGIES INC Management's Discussion and Analysis of Financial Condition a..
AQ
11/15Palatin Technologies, Inc. Reports Earnings Results for the First Quarter Ended Septemb..
CI
09/29PALATIN TECHNOLOGIES : Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Coliti..
PU
09/29Palatin Technologies, Inc. Reports Earnings Results for the Fourth Quarter Ended June 3..
CI
09/28PALATIN TECHNOLOGIES : Management's Discussion and Analysis of Financial Condition and Res..
AQ
09/27Palatin Technologies, Inc. Announces Presentation of Positive Protective Effects of PL8..
CI
09/17PALATIN TECHNOLOGIES : AMENDED AND RESTATED BY-LAWS OF (Form 8-K)
PU
09/17PALATIN TECHNOLOGIES INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year..
AQ
08/06PALATIN TECHNOLOGIES INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
More news
News in other languages on PALATIN TECHNOLOGIES, INC.
11/15Earnings Flash (PTN) PALATIN TECHNOLOGIES annonce un chiffre d'affaires de 159 482 $ po..
06/29Palatin Technologies et la FDA s'accordent lors d'une réunion sur les éléments de l'ess..
05/17Earnings Flash (PTN) PALATIN TECHNOLOGIES affiche un chiffre d'affaires de 88 741 $ au ..
2015Wall Street ouvre en baisse, la conjoncture mondiale inquiète
2015PALATIN TECHNOLOGIES : Feu vert aux USA à la commercialisation du "Viagra féminin"
More news
Analyst Recommendations on PALATIN TECHNOLOGIES, INC.
More recommendations
Chart PALATIN TECHNOLOGIES, INC.
Duration : Period :
Palatin Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PALATIN TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,55 $
Average target price 3,33 $
Spread / Average Target 506%
EPS Revisions
Managers and Directors
Carl Spana President, Chief Executive Officer & Director
Stephen T. Wills COO, CFO, Secretary, Treasurer & Executive VP
John K. A. Prendergast Non-Executive Chairman
Michael B. Raizman Chief Medical Officer
John Dodd Senior Vice President-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
PALATIN TECHNOLOGIES, INC.-18.54%127
GILEAD SCIENCES, INC.19.29%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.78%63 017
VERTEX PHARMACEUTICALS-13.24%52 137